Successful Treatment of EBV+ PTLD with Maribavir Following Allogeneic Stem Cell Transplantation for ATLL (ICBMT 2026) - Oct 8, 2026 - Abstract #PP06‑22; "GVHD prophylaxis with cyclosporine and mycophenolate was tapered within three months due to Pneumocystis jirovecii pneumonitis...Treatment included carmustine, brentuximab vedotin, venetoclax, azacitidine, and two donor lymphocyte infusions (5M/kg CD3+ T cells each). She developed severe liver and GI GVHD (bilirubin 15.4 mg/dL), requiring steroids, tacrolimus, mycophenolate, abatacept, ATG (1mg/kg), and ruxolitinib (40mg daily)... Approximately half of EBV+ PTLD cases show relapse or resistance to initial RIS or Rituximab‑based treatments. While no clinical trials have proven maribavir efficacy in EBV+ PTLD, this case demonstrates promising results in a complex post‑transplant setting with multiple complications, highlighting the need for further research in this unmet medical need. Keywords: Adult T cell Leukemia/Lymphoma, Post Transplant Lymphoproliferative Disorder (PTLD), Epstein Barr Virus, Maribavir"
Adult T-Cell Leukemia-Lymphoma • Epstein-Barr Virus Infections • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Obesity • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation
|
|
Fang‑Yu Wang 1; Min‑Feng Shih 1; Wei‑Han Huang 1, 2; Chi‑Cheng Li 1, 2
|